Zahra Mahmoudjafari, Pharm.D., MBA, is a clinical pharmacy manager in the Division of Hematologic Malignancies and Cellular Therapeutics at the University of Kansas Health System in Kansas City, Kansas. In this Managed Healthcare Executive K-Cast video series, Mahmoudjafari discussed a wide range of issues concerning bispecific antibodies as treatment of multiple myeloma, including their relationship to CAR-T therapy, formulary placement, some of the operational and financial challenges they pose and safety and toxicity issues.

Transformative treatment

The emergence of bispecific antibodies has transformed the treatment landscape for relapsed/refractory multiple myeloma by offering an immediate and accessible, off-the-shelf immunotherapy for patients with multiple myeloma, Mahmoudjafar

See Full Page